BridgeBio Pharma

News

BridgeBio two for two as rare disease drug aces ph3 trial

BridgeBio's week just went from great to superb, as it reports a second positive topline result in a pivotal trial of a late-stage pipeline drug.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.

News

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

News

Alnylam hails vutrisiran data, but investors seem sceptical

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t

News

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther

BridgeBio two for two as rare disease drug aces ph3 trial

Alnylam joins three-way contest in ATTR cardiomyopathy

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio poised to challenge Pfizer after Attruby approval

Alnylam hails vutrisiran data, but investors seem sceptical

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

BridgeBio Pharma

Editor's Picks